A growing body of evidence indicates that interactions between neoplastic cells and tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) are crucial in promoting tumor cell invasion and progression. Macrophages have an ambiguous role in these processes as this M1 phenotype correlates with tumoricidal capacity, whereas TAMs of M2 phenotype exert tumor-promoting effects. In this study, we provide evidence that interactions between mouse breast tumor cells and TAMs remodel the TME, leading to the upregulation of Fra-1, a member of the FOS family of transcription factor. In turn, this proto-oncogene initiates activation of the IL-6/JAK/Stat3 signaling pathway. This creates a malignant switch in breast tumor cells, leading to increased release of proangiogenic factors MMP-9, vascular endothelial growth factor and transforming growth factor-b from tumor cells and intensified invasion and progression of breast cancer. Proof of the concept for the crucial role played by transcription factor Fra-1 in regulating these processes was established by specific knockdown of Fra-1 with small interfering RNA, which resulted in a marked suppression of tumor cell invasion, angiogenesis and metastasis in a mouse breast cancer model. Such a strategy could eventually lead to future efficacious treatments of metastatic breast cancer.
Introduction
There is a growing body of evidence indicating that interactions between tumor cells and components of their microenvironment are crucial for malignant progression. Tumor-associated macrophages (TAMs) have an ambiguous role in this process as their M1 phenotype correlates with tumoricidal capacity, whereas TAMs of M2 phenotype exert a tumor-promoting effect (Balkwill et al., 2005) . Thus, large numbers of infiltrating TAMs correlate with poor clinical outcome in breast cancer patients (Leek and Harris 2002) . Metastatic disease occurs less frequently in breast tumor-bearing mice with defective recruitment of M2 macrophages than in mice that lack such cells . Also, cocultivation of breast cancer cells with M2 macrophages leads to enhanced invasiveness of tumor cells due to upregulated MMP9 (Hagemann et al., 2004) . In fact, TAMs are derived from circulating monocytic precursors and preferentially localize at the stroma-tumor interface (Lin et al., 2001; Pollard 2004) . They are recruited to the tumor site by cytokines, chemokines and other tumorderived factors, and, once situated in situ, produce additional chemokines, cytokines, as well as growth and proangiogenesis factors. The tumor microenvironment (TME) is thought to educate TAMs to express their M2 tumor-promoting phenotype (Pollard 2004; Condeelis and Pollard 2006; Lewis and Pollard 2006) . Thus, interactions between TAMs and tumor cells in the TME are important in regulating both tumor cytokine and growth factor networks, which are critical for the promotion of tumor cell invasion and progression.
It is well known that a high proportion of oncogenes encode transcription factors whose deregulated expression or activation as well as mutations and translocations have critical roles in tumorigenesis. The majority of oncogenic signaling pathways converge on sets of transcription factors that ultimately control gene expression patterns, resulting in tumor formation, progression and metastasis (Darnell, 2002) . In fact, the activator protein-1 (AP-1) family of transcription factors also includes transcription factors Fra-1 and c-Jun as major components (Adiseshaiah et al., 2005) . The overexpression of Fra-1 is a common mechanism of constitutive AP-1 activation in tumors (Milde-Langosch 2005) and has a crucial role in AP-1-mediated transformation of several cell types. Fra-1 expression in breast tumor cells is also associated with the aggressive behavior of several breast cancer cell lines (Philips et al., 1998; Zajchowski et al., 2001 ).
Interleukin 6 (IL-6) is a well-known pleiotropic cytokine whose expression is highly controlled under normal physiological conditions. However, it also serves as an immunomodulatory cytokine, which functions as a growth and differentiation factor for many cancer cells. At the level of transcriptional regulation, the function of IL-6 as a target gene for several different signaltransduction pathways is reflected by the fact that various transcription factors, such as AP-1 and nuclear factor-kB, can interact with the IL-6 promoter to initiate mRNA synthesis. Deregulated activation of the IL-6 promoter is, for the most part, mediated by combined, constitutively activated transcription factors. Thus, stromal cell-derived inflammatory cytokines, including IL-6 were reported to activate JAK/Stat3 signaling and initiate tumor generation.
In fact, JAK/Stat3 signaling seems to be an early adaptation to facilitate intercellular communication that has co-evolved with a plethora of other cellular signaling events. It is also well known that such highly adapted, ligand-specific signaling pathways control gene expression.
In this study, we report on the crucial role played by activated transcription factor Fra-1 and the IL-6/JAK/ Stat3 signaling pathway in modulating the TME, which leads to an increase in breast tumor invasion, angiogenesis and metastasis.
Results
TAMs but not normal macrophages overexpress transcription factors Fra-1, Stat3 and c-Jun Tumor-associated macrophages, in the TME, are recruited by chemokines produced by tumor cells to promote tumor progression and increase the rate of tumor angiogenesis and metastasis. Transcriptional regulation has a key role in both switching and maintaining the M2 phenotype and functions of TAMs in the TME. We demonstrate here for the first time that Fra-1, one of the members of the AP-1 family of transcription factors, is strongly expressed by TAMs in the 4T1 breast TME at both the RNA and protein levels (Figures 1a and b) . Macrophages of M2 phenotype (F4/ 80 þ cells) were isolated from 4T1 breast cancer tissue by magnetic-activated cell sorting at >95% purity as determined by fluorescence-activated cell sorting analysis. This was further confirmed by immunofluorescence staining analyses visualized by multiple color fluorescence microscopy. Fra-1 expression in TAMs from 4T1 tumor tissue was evident (Figure 1c ) by double staining with anti-Fra-1 antibody (green) combined with anti-macrophage F4/80 antibody (red). In addition, tumor-infiltrating macrophages were visualized by hematoxylin and eosin staining, and the high level of c-Jun, required to form a heterodimer with Fra-1, could be detected in TAMs by reverse transcription-PCR and western blotting (Figures 1a and b) .
Autocrine IL-6 has been implicated as an important activator of oncogenic transcription factor Stat3 and the Jagged-1/Notch signaling pathway (Gao et al., 2007) . Earlier studies support these data as we also found that the IL-6/JAK/Stat3 signaling pathway and cytokines IL-4, IL-6 and IL-10 are more highly activated in TAMs of M2 phenotype than in M1 macrophages (Supplementary Figure 1 ). These data were also supported by reverse transcription-PCR and western blots indicating IL-6, Stat3 and p-Stat3 to be more upregulated in F4/ 80-positive macrophages in the TME of 4T1 breast tumors than in macrophages from normal mouse spleen ( Figure 1d ). Importantly, culture of RAW mouse macrophages with cytokines primarily released from tumor cells such as IL-4, 6, 10, 13 and granulocytemacrophage-colony-stimulating factor. The expressions of Stat3 and p-Stat3 in those cells were upregulated when compared with that of RAW wild-type cells (Figure 1e ).
Interactions between TAMs and 4T1 breast tumor cells upregulate Fra-1, Stat3 and IL-6 in TAMs and increase expression of downstream target genes VEGF, MMP-9 and TGF-b of the IL-6/JAK/Stat3 signaling pathway Interactions between macrophages and tumor cells can lead to functional changes and maintenance of the M2 phenotype of TAMs in the TME Sica et al., 2006) ; however, the underlying molecular mechanism(s) of these events still remains largely unknown. To gain a better understanding of such mechanism(s), we co-cultured TAMs with 4T1 tumor cells to assess if interactions between these cells can activate Fra-1 and the IL-6/JAK/Stat3 signaling pathway in TAMs. Indeed, we found upregulated expression of Fra-1 in M2 macrophages after 72 h by intracellular staining and flow cytometry analyses ( Figure 2a) . Moreover, the expression of IL-6 and Stat3 was also upregulated during this co-culture experiment (Figures 2b and c) .
The ability of transcription factor Stat3 to regulate many aspects of oncogenesis has been well documented, including tumor-cell proliferation, migration, survival and angiogenesis. Upon co-culture of TAMs with 4T1 tumor cells, we found a correlation between activation of the IL-6/JAK/Stat3 signaling pathway and the expression of its downstream target genes MMP-9, vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-b, which support tumor progression. In fact, we detected a significantly upregulated expression of these proangiogenesis factors in M2 macrophages, but not in 4T1 cells, by intracellular staining and flow cytometry analyses after 96 h co-culture (Figures 3a and b) .
Knockdown of Fra-1 in RAW macrophages by siRNA downregulates IL-6 and Stat3, decreases the release of proangiogenesis factors and inhibits migration and invasion of 4T1 breast cancer cells At the level of transcriptional regulation, Fra-1 can interact with the IL-6 promoter to initiate mRNA synthesis. We found that expression of Fra-1 also correlates with activation of the IL-6/JAK/Stat3 signaling pathway in TAMs. To confirm this finding and to determine whether Fra-1 is responsible for activation of this signaling pathway in TAMs, we generated a Fra-1 small interfering RNA (siRNA) system which knocked down translation of Fra-1 mRNA in RAW cells. Indeed, we found that expression of both Fra-1 and Stat3 was knocked down in these macrophages by siRNA ( Figures  4a and b) . Interestingly, co-culture of 4T1 tumor cells with wild-type RAW cells markedly increased IL-6 release, an effect that was inhibited when 4T1 tumor cells were co-cultured with RAW cells subjected to knockdown of Fra-1 (Figure 4c ). In fact, knockdown of Fra-1 expression downregulated the IL-6/JAK/Stat3 signaling pathway. Intracellular staining indicated that expression of Fra-1 in TAMs is also responsible for activation of Stat3 downstream target genes as indicated by the increased release of MMP-9, TGF-b and VEGF. In fact, our results showed that release of these same factors was decreased when RAW cells were subjected to Fra-1 knockdown (Figure 4d ).
Migration and invasion assays demonstrataed that activation of Fra-1 and the IL-6/JAK/Stat3 signaling pathway in TAMs enhances tumor cell invasion and metastases. Thus, the data depicted in Figures 4e and f indicate that migration and invasion of 4T1 cells were both enhanced by co-culture with wild-type RAW cells, but not with RAW cells subjected to Fra-1 knockdown. Apparently, activation of Fra-1 in TAMs can enhance the malignancy of 4T1 tumor cell by activating the IL-6/JAK/Stat3 signaling pathway. This raises the possibility that inhibition of both this pathway and Fra-1 in TAMs may remodel the TME resulting in suppression of tumor progression.
Suppression of tumor angiogenesis and tumor progression occurs after co-implantation into Balb/c mice of 4T1 tumor cells and RAW macrophages subjected to knockdown of Fra-1 On the basis of the above in vitro results, we hypothesized that both, Fra-1 and the IL-6/JAK/Stat3 signaling pathway have important roles in determining the TAM phenotype and in promoting tumor growth and angiogenesis in vivo. To prove this hypothesis, Balb/c mice were depleted in vivo of macrophages by clodronate liposomes 2 days before 4T1 tumor cell challenge. These mice were then injected orthotopically into the fat pad with 1 Â 10 4 4T1 tumor cells, which had been previously admixed with either RAW cells subjected to Fra-1 knockdown or wildtype RAW cells at a ratio of 7:3 (4T1: RAW). As depicted schematically, all mice were killed on day 23 after tumor cell injection and tumor samples harvested for further experiments ( Figure 5a ). We verified that downregulation of Fra-1 in RAW cells by siRNA that occurred in the 4T1 tumor tissue also resulted in decreased expression of Stat3 and p-Stat3 (Figures 5b-d) .
Furthermore, downregulation of proangiogenesis factors MMP-9, VEGF and TGF-b was detectable by immunohistochemical staining of 4T1 tumor tissue sections obtained only from those mice that were coimplanted with RAW cells subjected to Fra-1 knockdown ( Figure 6a ). These findings suggest that the downregulated expression of Fra-1 in TAMs can change their phenotype, thus causing a decreased release of proangiogenesis factors. This antiangiogenesis decreased the expression of the endothelial cell marker CD31 whenever 4T1 tumor cells were co-implanted with RAW cells subjected to Fra-1 knockdown ( Figure 6b ). These results were confirmed by Masson's trichrome staining indicating blood vessel growth in tumor tissues 23 days after 4T1 tumor cell implantation ( Figure 6b ). Analysis of RAW cells after Fra-1 knockdown indicated a 10 to 20% lower expression of MMP-9, TGF-b and VEGF than RAW wild-type cells.
We further demonstrated that both Fra-1 and the IL-6/JAK/Stat3 signaling pathway in TAMs have a key role in 4T1 breast tumor growth and progression. To this end, we depleted Balb/c mice in vivo of macrophages, and then challenged them with 4T1 tumor cells that were prior admixed with either Fra-1 knockdown or wild-type RAW cells, respectively. Tumor growth in mice injected with 4T1/RAW wild-type cells was much more rapid than that observed in mice injected with 4T1/ RAW-Fra-1 knockdown cells (Figure 7a ). Another experiment demonstrated that 75% of mice (3/4) injected with 4T1/RAW Fra-1 knockdown cells did not grow any tumors in contrast to mice injected with 4T1/RAW wild-type cells, all of which presented with large tumors (4/4) ( Figure 7b ). Moreover, analyses of spontaneous lung metastases originating from these 4T1 tumors indicated that wildtype RAW macrophages markedly enhanced 4T1 tumor cell metastasis to lung. However, such metastases were completely inhibited by knockdown of Fra-1 expression in TAMs (Figures 7c and d) . The lack of lung metastases could certainly contribute to the decrease in tumor size, which may not be solely due to knockdown of Fra-1.
In summary, Fra-1 expression in TAMs was decisively upregulated by their interaction with 4T1 breast cancer cells. As outlined schematically (Figure 7e ), we propose that the strongly activated Fra-1/c-Jun complex may bind with the control region of AP-1 on the IL-6 promoter and lead to the upregulation of IL-6 expression in TAMs. In turn, it is possible that large amounts of IL-6 released from TAMs could, by a feedback mechanism, bind with gp130, which is a part of the receptor complex for IL-6 on the TAM membrane. This, in turn, might lead to the activation of the IL-6/JAK/ Stat3 signaling pathway in TAMs which is responsible for upregulation of key growth and proangiogenesis factors that strongly support 4T1 breast tumor cell growth, angiogenesis, invasion and metastasis.
Discussion
In this study, we demonstrated the crucial role played by activation of both, transcription factor Fra-1 and the 
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Figure 5 Downregulated expression of Stat3 in tumor-associated macrophages in Balb/c mice after co-implantation with 4T1 cells and RAW macrophages subjected to Fra-knockdown. (a) Scheme depicting the experimental approach: groups of mice, which were depleted of macrophages 2 days before 1 Â 10 4 4T1 tumor cell challenge, were injected into the fat pad with either RAW cells subjected to Fra-1 knockdown or wild-type RAW cells at a ratio of 4T1 cells: RAW cells of 7:3. All mice were killed on day 23 after tumor cell challenge and tumors harvested for further experiments; (b) expression of Fra-1 (green) in RAW cell observed in a 4T1 tumor model which was co-implanted with RAW cells subjected to Fra-1 knockdown or wild-type RAW cells were detected by immunofluorescence staining. To visualize RAW cell in tumor tissue, the frozen 4T1 tumor tissue was incubated with anti-F4/80 antibody (red) and DAPI (blue) was used to visualize cell nuclei. The expression of Stat3 (c) and p-Stat3 (d) in RAW cell in the same 4T1 tumor section was visualized by immunofluorescence staining.
IL-6/JAK/Stat3 signaling pathway in TAMs that was induced by interactions between TAMs and 4T1 breast cancer cells in the TME. We established proof of the concept that these events are critical for achieving the marked increase in angiogenesis, invasion and metastasis observed in 4T1 breast tumor cells in vitro and in vivo.
Tumor-associated macrophages have been increasingly recognized for their critical roles played in the TME in promoting tumor progression (Lin and Pollard 2007; and tumor angiogenesis resulting in matrix remodeling (Coussens et al., 2000) . This establishes a premetastatic niche in the lung (Hiratsuka et al., 2006) , and aids in suppressing adaptive immunity against tumor cells (Bronte and Zanovello 2005) . TAMS have also been observed in the microenvironment of malignant tumors (Allavena et al., 2008; Martinez et al., 2008) . In fact, results of our earlier studies (Luo et al., 2006) are consistent with these reports by demonstrating that inhibition of tumor growth and metastasis correlates with a markedly decreased density of TAMs in the TME. Our current study similarly indicates that the macrophage phenotype switched from M1 to M2 after co-culture with 4T1 tumor cells. This switch in phenotype is key to the development of TAMs and has a major role in the increased release of proangiogenesis factors MMP-9, VEGF and TGF-b from these cells, which promote increased tumor cell invasion and metastasis.
The potential of transcription factors Fra-1 and Stat3 operative in TAMs in promoting tumor progression and metastasis was pointed out in two of our previous findings and provided the basic rationale for the current study. Thus, ablation of TAMs was achieved by a DNA vaccine targeting a specific marker, Legumain, an asparaginyl endopeptidase overexpressed on TAMs. This caused a marked CD8 þ T-cell-mediated suppression of tumor growth and metastasis in several mouse tumor models. This finding can be attributed, in part, to a significant reduction in release of tumor growth and proangiogenesis factors from TAMs. These factors have key roles in the formation of the tumor vasculature and initiation of tumor angiogenesis, growth and metastasis (Luo et al., 2006; Lewen et al., 2008) . Data from our earlier DNA microarray assays of TAMs in the breast cancer TME also indicated a marked overexpression of IL-6, as well as high levels of Fra-1, IL-6 and Stat3 detectable in TAMs isolated from primary tumor tissues in a mouse 4T1 breast tumor model (Supplementary Figure 1) . Together, these earlier findings strongly suggested that Fra-1 and the IL-6/JAK/Stat3 signaling pathway are operative in TAMs. Although the roles of the IL-6/JAK/Stat3 signaling pathway in tumor cells had already been thoroughly investigated (Hodge et al., 2005; Kortylewski and Yu 2008) , the correlation between the expression of Fra-1 and activation of the IL-6/JAK/Stat3 signaling pathway as well as the pathophysiological effects of Fra-1 on the malignant M2 phenotype of TAMs had not been established thus far. On the basis of our current results, we propose that the key roles in transcriptional regulation played by Fra-1 and the IL-6/JAK/Stat3 signaling pathway in maintaining the malignant M2 phenotype of TAMs are most likely also important in regulating and remodeling the TME of breast tumors. In fact, our initial study (Supplementary Figure 1) indicates that both the Fra-1/ c-Jun complex and the IL-6/JAK/Stat3 signaling pathway were highly activated in TAMs prominent in the TME. However, several key questions involving mechanisms responsible for these phenomena need yet to be answered. These include whether and how Fra-1 is linked with IL-6/JAK/Stat3 signaling in TAMs and what function(s) is controlled by this linkage. In this regard, the function of IL-6 at the level of transcriptional regulation was shown to be regulated by interactions of various transcription factors with the IL-6 promoter. In fact, it was demonstrated that activation of the IL-6/Stat3 signaling pathway in TAMs as well as in other immune components of the TME is a critical event (Kortylewski et al., 2005; Yu et al., 2007) .
Here we established that Fra-1, together with its partner c-Jun, is highly expressed in TAMs and that there is indeed a correlation between Fra-1, IL-6 and Stat3 expression in TAMs. However, as different mechanisms are responsible for activating the IL-6/ JAK/Stat3 signaling pathway in different cell types (Asschert et al., 1999; Faggioli et al., 2004) , it is not yet clear if Fra-1 is solely responsible for upregulation and activation of the IL-6/JAK/Stat3 signaling pathway in TAMs. In fact, during the analysis of the mouse IL-6 promoter, several AP-1 sites were identified in the promoter region of the IL-6 gene and Fra-1 could activate the IL-6 promoter in prostate cancer cells as demonstrated by electrophoretic mobility shift assays (Zerbini et al., 2003) . On the basis of our prior and current data, we propose that upregulated Fra-1 can bind to the AP-1 element of the IL-6 promoter in TAMs and then induce activation of the IL-6/JAK/Stat3 signaling pathway and its downstream target genes MMP-9, VEGF and TGF-b. These are most likely a critical series of events, as all these genes contribute in promoting tumor angiogenesis, invasion and metastasis.
We provided here multiple lines of evidence from our in vivo and in vitro experiments which strongly support the conclusions that the Fra-1 and IL-6/JAK/Stat3 signaling axis can initiate tumor angiogenesis through activation of a set of downstream target genes of Stat3 that encode proangiogenesis factors. This indicates that activation of Fra-1 as well as that of the IL-6/JAK/ Stat3 signaling pathway can indeed impede the major biological functions of TAMs. These contentions are further supported by the data of others indicating that the restoration of the M1 phenotype in TAMs may provide therapeutic benefits in tumor-bearing mice (Guiducci et al., 2005) . These data also suggest that switching the TAM phenotype from M2 to M1 during tumor progression may promote antitumor activities. Alternatively, our findings presented here indicate that an antitumor effect can also be achieved by a specific siRNA-mediated knockdown of Fra-1 and by blocking the activation of the IL-6/JAK/Stat3 signaling pathway. Approaches such as these would most likely change the normal biological function of TAMs and thereby achieve a marked suppression in breast cancer invasion and metastasis, a strategy that could eventually lead to future improvement in the treatment of metastatic breast cancer.
In summary, the findings of this study underline the importance of delineating potential mechanisms that regulate breast cancer cell invasion and metastasis mediated by TAMs in the TME. Our data also emphasize that interaction between TAMs and 4T1 breast tumor cells in our experimental mouse breast tumor model did indeed have a pivotal role in tumor progression and metastasis. Furthermore, the transcriptional regulation of Fra-1 and the IL-6/JAK/Stat3 signaling pathway may indeed have a key role in these events and result in the modification and maintenance of the malignant phenotype of TAMs.
Materials and methods

Animals and cell lines
Female Balb/c mice, 6-to 8-weeks of age, were purchased from the Scripps Research Institute Rodent Breeding Facility (La Jolla, CA, USA). All animal experiments were performed according to National Institutes of Health guidelines. The 4T1 mammary carcinoma cell line was generously provided by Dr Suzanne Ostrand-Rosenberg (University of Maryland, Baltimore). The RAW 264.7 macrophage cell line was purchased from ATCC (Manassas, VA, USA). Our animal protocol was approved by The Scripps Research Institute Institutional Animal Care and Use Committee.
Isolation of TAMs from tumor tissue by magnetic-activated cell sorting Tumor tissues were minced into small pieces and then incubated for 1 h at 37 1C in 5 ml of HBSS (10% fetal calf serum) containing 125 U/ml of collagenase I (Gibco-BRL, Carlsbad, CA, USA), 60 U/ml of Dnase I and 60 U/ml of hyaluronidase (Sigma, St Louis, MO, USA). Supernatants were harvested and then depleted of RBC with ACK. Cell suspensions were passed through a fine screen mesh and then several times through a #25 needle. Cell pellets were resuspended and labeled with biotinylated rat anti-mouse F4/ 80 Ab (Caltag Laboratories, Carlsbad, CA, USA) using 0.1-0.25 mg Ab/1 Â 10 6 cells in 100 ml staining buffer. Streptavidin microbeads were added at 10 ml per10 7 cells and then incubated 15 min at 4-8 1C. Up to 10 8 cells were re-suspended in 500 ml of separating buffer and applied to an LS column in a magnetic field (Miltenyi Biotec, Bergisch Gladbach, Germany). Unlabeled cells that passed through the column were collected, as were retained cells after removal of the magnetic field.
Co-culture assay 4T1 breast carcinoma cells were co-cultured with either RAW macrophage cells or macrophages derived from normal mouse spleen or from breast tumor tissue with or without cellto-cell contact. Briefly, for migration or invasion assays, 3 Â 10 5 macrophages were seeded in Transwell inserts (0.2-mm pores; Nunc, Rochester, NY, USA), consisting of a membrane permeable for liquids but not cells. The transwells were then inserted into a six-well plate and 8 Â 10 5 4T1 tumor cells were added to the bottom of each well. For cytometry analysis, 8 Â 10 5 /ml 4T1 tumor cells were mixed with 2 Â 10 5 /ml macrophages in a flask and then cultured at different time points together at 37 1C, 5% CO 2 .
Macrophage depletion in vivo by clodronate liposomes Macrophages were depleted by injection of freshly prepared clodronate-containing liposomes as described (van and Sanders 1994; Fraser et al., 1995; Knudsen et al., 2002) . Clodronate was a gift from Roche Diagnostics GmbH (Mannheim, Germany). Mononuclear phagocytes ingest the clodronate-containing liposomes and disrupt the liposomal bilayers with phospholipase, resulting in intracellular release of clodronate and subsequent cell death (van 1989) . A dose of 100 ml per 10 g of mouse body weight of clodronate liposomes diluted in phosphate-buffered saline was selected and administered intravenously to Balb/c mice every week. The first injection was administered 2 days before the start of the experiment. Control mice were administered either phosphatebuffered saline as a control for unstimulated macrophages or liposomes in saline to control for any nonspecific effects of liposome administration. Macrophage depletion was maintained throughout the experimental period.
Immunohistochemical analyses
Immunohistochemical fluorescence staining. These were performed on 4T1 tumor tissues with Fra-1 expression of macrophages being identified by rat anti-mouse F4/80 mAb (ABD serotec, Raleigh, NC, USA) with goat anti-rat IgG Alexa 568 (Invitrogen, Carlsbad, CA, USA) as the secondary reporter reagent. Rabbit anti-Fra-1, anti Stat3 or antip-Stat3 antibody was purchased from Santa Cruz (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Reactions were visualized with goat anti-rat IgG Alexa 488 (Invitrogen), and slides were analysed by fluorescence microscopy (Olympus, Hamburg, Germany).
Immunohistochemical (DAB) staining. 4T1 tumor tissue sections were fixed and stained with the Rabbit immunoCruz staining system (Santa Cruz Biotechnology Inc.), using rabbit anti-murine MMP-9, VEGF, TGF-b and CD31 mAbs. A horseradish peroxidase-conjugated goat-anti-mouse secondary Ab was used and slides mounted with cells to be visualized microscopically.
Hematoxylin and eosin and Masson's trichrome staining. This was performed by the Histology facility of The Scripps Research Institute. All images were captured by a Spot Cooled Color Digital Camera System (Diagnostic Instruments Inc., Sterling Heights, MI, USA).
Flow cytometry analyses
Flow cytometry was used for detection of intracellular expression of Fra-1, IL-6, Stat3 as well as growth factors MMP-9, TGF-b and VEGF. Macrophages, collected at different time points after co-culture with 4T1 tumor cells, were assayed according to the instructions provided by the manufacturer (BD Bioscience, San Jose, CA, USA). Briefly, macrophage markers F4/80, CD45 and Fra-1, IL-6, Stat3 as well as growth factors MMP-9, TGF-b and VEGF were measured by three-color flow cytometry analysis with a BD Biosciences Digital LSR II. Macrophages were harvested from co-culture and then stained with anti-F4/80 Ab conjugated with antigen-presenting cell and anti-CD45 Ab conjugated with pacific blue. After fixation and permeabilization, cells were stained with anti-Fra-1, IL-6, Stat3 Abs as well as antigrowth factor MMP-9, TGF-b and VEGF Abs conjugated with fluorescein isothiocyanate and then followed by fluorescence-activated cell sorting analyses. All antibodies were purchased from BD Biosciences.
Reverse transcription-PCR and western blotting
Reverse transcription-PCR. Total RNA was extracted with the Rneasy mini Kit (Qiagen, Valencia, CA, USA) using 3 Â 10 6 TAMs or normal macrophages from mouse spleen as well as from 4T1 breast carcinoma cells. Reverse transcription was carried out with 1 mg of total RNA followed by PCR with the appropriate oligonucleotides.
Western blots. These were performed with the total protein from cell lysate homogenates, using polyclonal primary rabbit anti-murine Fra-1 c-Jun, IL-6, Stat3 or pStat3 antibodies and anti-murine -actin antibody as a loading control (Santa Cruz Biotechnology Inc.). Specific protein was detected with a goat anti-rabbit-horseradish peroxidase-conjugated IgG antibody (Bio-Rad, Richmond, CA, USA).
SiRNA gene silencing
We used the siRNA gene Silencer system of Santa Cruz Biotechnology Inc. to perform the Fra-1 gene silencing in RAW macrophages by following the instructions provided by the manufacturer.
Migration and invasion assays
Transwell migration assays were performed with 4T1 tumor cells being harvested from co-culture with either RAW macrophages subjected to Fra-1 knockdown or wild-type RAW macrophages by using modified Boyden chambers (Transwell; Corning Inc., Corning, NY, USA). After 4 h culture, cells on the lower surface of wells were fixed with 1% paraformaldehyde, stained with 1% crystal violet, and counted. Cell invasion assays were performed by using a CytoSelect 24-well cell invasion kit (Cell Biolabs Inc., San Diego, CA, USA).
Statistics
The statistical significance of differential findings between experimental groups and controls was determined by Student's t-test. Findings were regarded as significant if two-tailed P-values were less than 0.05. Kaplan-Meier analysis was used to evaluate the survival time of mice.
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